HWAM
ARQT icon

Hennion & Walsh Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,968
Closed -$409K – 855
2024
Q3 		$409K Sell
43,968
-4,618
-10% -$45.6K 0.02% 665
2024
Q2 		$452K Sell
48,586
-411
-0.8% -$3.72K 0.02% 616
2024
Q1 		$486K Buy
48,997
+6,155
+14% +$45.9K 0.03% 574
2023
Q4 		$138K Sell
42,842
-52,466
-55% -$143K 0.01% 798
2023
Q3 		$506K Sell
95,308
-7,105
-7% -$60.4K 0.03% 515
2023
Q2 		$976K Sell
102,413
-34,391
-25% -$382K 0.06% 377
2023
Q1 		$1.5M Buy
136,804
+4,032
+3% +$58.3K 0.09% 262
2022
Q4 		$1.97M Buy
132,772
+42,508
+47% +$743K 0.12% 210
2022
Q3 		$1.73M Sell
90,264
-2,389
-3% -$54.1K 0.11% 211
2022
Q2 		$1.97M Buy
92,653
+5,284
+6% +$108K 0.12% 205
2022
Q1 		$1.68M Buy
87,369
+22,021
+34% +$373K 0.09% 247
2021
Q4 		$1.35M Buy
65,348
+34,752
+114% +$692K 0.07% 298
2021
Q3 		$731K Buy
30,596
+10,477
+52% +$239K 0.04% 425
2021
Q2 		$549K Buy
+20,119
New +$567K 0.03% 504

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Hennion & Walsh Asset Management's ARQT Position: Q4 2024 in Review

Hennion & Walsh Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 43,968 shares — an estimated $409K sold.

Hennion & Walsh Asset Management first reported a position in ARQT in Q2 2021 and held it in 14 quarters. The position peaked at $1.97M in Q2 2022. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Hennion & Walsh Asset Management reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 43,968 Arcutis Biotherapeutics shares in Q4 2024, an estimated $409K.
  • Hennion & Walsh Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 14 quarters.
  • Hennion & Walsh Asset Management's Arcutis Biotherapeutics position peaked at $1.97M in Q2 2022.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2024, filed 15 Jan 2025.